CD19 and systemic lupus erythematosus: Notably, a 21-year-old man with SLE and progressive transverse myelitis showed improved neurological function, muscular strength, and regression of MRI lesions after treatment with a second-generation CAR T-cell therapy (CD19 binder and 4-1BB co-stimulation), along with decreased CSF protein (109).